NPPB and heart failure: The EMPACT-MI and EMMY trials demonstrated that early administration of empagliflozin may improve cardiac function, accelerate NT-proBNP reduction, and support reverse remodeling, indicating a possible benefit in preventing heart failure progression in this population [24,25].